Shots:

• The four P-III ContRAst -1- 2- 3 & X studies will assess otilimab (90mg/150mg- SC- qw) vs PBO- tofacitinib (5mg- bid)- sarilumab (200mg- SC) all in combination with MTX/ DMARDs in patients with RA- following the results of P-II BAROQUE study  
• The 1EPs & 2EPs of P-III ContRAst studies will be ACR20 @12wks. against PBO & CDAI score and HAQ-DI score and pain against PBO- tofacitinib/sarilumab and the studies will be conducted across 32 countries
• Otilimab (GSK3196165) is a mAb targeting granulocyte-macrophage colony-stimulating factor (GM-CSF)- act by blocking its interaction with its cell surface receptor. In 2013- MorphoSys granted exclusive WW development and commercialization rights of Otilimab to GSK

Click here to read full press release/ article

Ref: GSK | Image: GSK